These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28684062)

  • 1. Intracoronary high-dose bolus tirofiban administration during complex coronary interventions: A United States-based case series.
    Wilmer CI
    Cardiovasc Revasc Med; 2018; 19(1 Pt B):112-116. PubMed ID: 28684062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
    Laine M; Panagides V; Frère C; Cuisset T; Gouarne C; Jouve B; Thuny F; Paganelli F; Alessi MC; Mancini J; Bonello L
    J Thromb Haemost; 2019 Dec; 17(12):2188-2195. PubMed ID: 31351022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of intracoronary versus intravenous high-dose bolus administration of tirofiban in diabetic patients undergoing primary percutaneous coronary intervention.
    Ghonim AA; Mostafa A; Emara A; Algazzar AS; Qutub MA
    Cardiovasc J Afr; 2019 Sep/Oct 23; 30(5):285-289. PubMed ID: 31194213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracoronary compared with intravenous bolus tirofiban on the microvascular obstruction in patients with STEMI undergoing PCI: a cardiac MR study.
    Ma Q; Ma Y; Wang X; Li S; Yu T; Duan W; Wu J; Wen Z; Jiao Y; Sun Z; Hou Y
    Int J Cardiovasc Imaging; 2020 Jun; 36(6):1121-1132. PubMed ID: 32078096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial.
    Lee W; Suh JW; Park JJ; Yoon CH; Cho YS; Youn TJ; Chae IH
    BMC Cardiovasc Disord; 2018 Oct; 18(1):201. PubMed ID: 30348101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of GP IIb/IIIa inhibitor duration on the clinical prognosis of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction with no-/slow-reflow phenomenon.
    Hu X; Wang W; Ye J; Lin Y; Yu B; Zhou L; Zhou Y; Dong H
    Biomed Pharmacother; 2021 Nov; 143():112196. PubMed ID: 34560551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Atherothromboaspiration a Possible Solution for the Prevention of No-Reflow Phenomenon in Acute Coronary Syndromes? Single Centre Experience and Review of the Literature.
    Manolis AS
    Curr Vasc Pharmacol; 2019; 17(2):164-179. PubMed ID: 29298651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention.
    Fabris E; Ottervanger JP; Hermanides RS; Ten Berg JM; Sinagra G; Koopmans PC; Giannitsis E; Hamm C; van 't Hof AWJ
    Catheter Cardiovasc Interv; 2019 Apr; 93(5):E293-E297. PubMed ID: 30585388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
    Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Outcome of Acute Coronary Syndromes in Patients on Chronic Oral Anticoagulants: Data from the EPICOR Study.
    Stepinska J; Wojtkowska I; Annemans L; Danchin N; Pocock SJ; de Werf FV; Medina J; Bueno H
    Curr Vasc Pharmacol; 2020; 18(1):92-99. PubMed ID: 30588886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of the coronary thrombus burden with all-cause mortality and major cardiac events in ST-segment elevation myocardial infarction patients treated with tirofiban.
    Tatlisu MA; Kaya A; Keskin M; Uzman O; Borklu EB; Cinier G; Hayiroglu MI; Eren M
    Coron Artery Dis; 2016 Nov; 27(7):543-50. PubMed ID: 27341666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of standard-dose versus half-dose tirofiban in patients with non-ST elevation acute coronary syndromes undergoing early percutaneous coronary intervention.
    Li W; Fu X; Xue H; Wang Y; Wang X; Zhao Y; Geng W; Yang Z; Gu X; Hao G; Jiang Y; Fan W; Wu W; Li S
    Cardiovasc Ther; 2013 Aug; 31(4):210-4. PubMed ID: 22954393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
    Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
    Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI.
    Hermanides RS; van Werkum JW; Ottervanger JP; Breet NJ; Gosselink AT; van Houwelingen KG; Dambrink JH; Hamm C; ten Berg JM; van 't Hof AW;
    Catheter Cardiovasc Interv; 2012 May; 79(6):956-64. PubMed ID: 22162050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
    Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY
    Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes.
    Lettino M; Andell P; Zeymer U; Widimsky P; Danchin N; Bardaji A; Barrabes JA; Cequier A; Claeys MJ; De Luca L; Dörler J; Erlinge D; Erne P; Goldstein P; Koul SM; Lemesle G; Lüscher TF; Matter CM; Montalescot G; Radovanovic D; Sendón JL; Tousek P; Weidinger F; Weston CFM; Zaman A; Li J; Jukema JW;
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):198-213. PubMed ID: 28329196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome].
    Turkmen S; Fettser DV; Kagliian KÉ; Serchelik A; Arystanova AZh; Tekin K; Balli M; Batyraliev TA; Samko AN; Sidorenko BA
    Kardiologiia; 2013; 53(1):23-7. PubMed ID: 23548346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspiration thrombectomy and intracoronary tirofiban in ST-segment elevation myocardial infarction : Combination treatment for patients undergoing primary percutaneous coronary intervention.
    Geng T; Zhang JG; Song ZY; Dai SP; Luo Y; Xu ZS
    Herz; 2016 Dec; 41(8):732-740. PubMed ID: 27220978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A patient with an extensive coronary artery thrombus.
    Chalikias G; Kikas P; Thomaidis A; Serif L; Georgiadis GS; Tziakas D
    Hellenic J Cardiol; 2018; 59(6):347-348. PubMed ID: 29126949
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and Safety of Thrombectomy Combined with Intracoronary Administration of Tirofiban in ST-segment Elevation Myocardial Infarction (STEMI).
    Gao L; Cao Z; Zhang H
    Med Sci Monit; 2016 Jul; 22():2699-705. PubMed ID: 27475844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.